Dual antiplatelet therapy (DAPT) is considered essential in clinical management of patients undergoing percutaneous coronary revascularization or acute coronary syndromes. However, the optimal platelet inhibition is not always obtained, with high residual platelet reactivity (HRPR) increasing stent thrombosis and recurrent ischemic events. Aim of this study was to investigate the impact of body mass index (BMI) on platelet reactivity in patients on DAPT.
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor
VERDOIA, Monica;SARTORI, Chiara;ROLLA, Roberta;BARBIERI, Lucia;SCHAFFER, Alon;MARINO, Paolo;BELLOMO, Giorgio;DE LUCA, GIUSEPPE
2015-01-01
Abstract
Dual antiplatelet therapy (DAPT) is considered essential in clinical management of patients undergoing percutaneous coronary revascularization or acute coronary syndromes. However, the optimal platelet inhibition is not always obtained, with high residual platelet reactivity (HRPR) increasing stent thrombosis and recurrent ischemic events. Aim of this study was to investigate the impact of body mass index (BMI) on platelet reactivity in patients on DAPT.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
59..pdf
file disponibile agli utenti autorizzati
Tipologia:
Altro materiale allegato
Licenza:
DRM non definito
Dimensione
292.4 kB
Formato
Adobe PDF
|
292.4 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
